IVVD
The market liked the tune-up
Invivyd popped after the company said its Phase 3 DECLARATION study for VYD2311 has already shown enough statistical power to back high efficacy, even though the trial isn’t fully finished yet. Translation: the data looked good enough that management decided to widen the study by 500 more subjects.
Why that matters
For biotech, this is the equivalent of a chef tasting the soup early and deciding to make a bigger pot. If the math still holds up with a larger sample, that’s usually a confidence signal investors notice fast — especially when the name is tied to a COVID-19 prevention asset.
The annoying part? Timing moved
The bigger trial means the finish line got pushed back a bit, with results now expected in the third quarter of 2026. So yes, there’s more potential upside here, but also a longer wait before the market gets the full reveal.
And then there’s the measles curveball
On top of the COVID program, Invivyd also highlighted a new measles antibody discovery, which gives the company another possible shot at expanding its pipeline. That’s the kind of news that can make a tiny biotech look a little less like a one-trick pony.
Big picture: the stock reaction says investors are leaning into the “promising data” part and shrugging off the longer timeline — at least for now.